Clinical trials: Stroke/Brain Attack
Ischemic Stroke
Electric Field Navigated 1hz Rtms for Post-stroke Motor Recovery Trial
A prospective, multi-center, randomized, sham-controlled, blinded study combining active Nexstim NBS-guided 1Hz rTMS or sham-rTMS targeting the healthy hemisphere with standardized task oriented rehabilitation will be conducted…
- Trial name
- E-FIT (NCT03010462)
- Testing
- Nexstim NBS guided active rTMS
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Nexstim Ltd
Atrial Fibrillation
Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon
Existing real-world studies have provided evidence that novel oral anticoagulants (NOACs) in general and rivaroxaban in particular are more effective and at least as safe as warfarin in non-valvular atrial fibrillation (NVAF)…
- Trial name
- ReLoaDeD (NCT03563937)
- Testing
- Phenprocoumon, Apixaban, Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Germany
- Volunteers
- 64,920 people
- Sponsor
- Bayer
Ischemic Stroke
Phase 2 Study of TXA127 in Post-ischemic Stroke Patients
This is a 50-patient, Phase 2, double-blind, randomized, placebo-controlled, hybrid decentralized study to evaluate the safety and efficacy of daily subcutaneous (SC) injection of TXA127 in post-ischemic stroke patients.
- Trial name
- NCT06135103
- Testing
- talfirastide
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Constant Therapeutics LLC
Atrial Fibrillation
Study to Evaluate the Use of Direct Oral Anticoagulants in UK Clinical Practice For Patients With a First Stroke Attributable to Nonvalvular Atrial Fibrillation
National Institute of Health and Care Excellence (NICE) guidance recommends anticoagulation for stroke prevention in high risk patients with nonvalvular atrial fibrillation (AF).
- Trial name
- NCT05262322
- Testing
- Edoxaban, Apixaban, Rivaroxaban
- Where
- 8 sites in United Kingdom
- Volunteers
- 234 people
- Sponsor
- Daiichi Sankyo UK Ltd, a Daiichi Sankyo Company
Pseudobulbar Affect (PBA), Stroke
Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)
The objectives of the study are to evaluate the safety, tolerability, and effectiveness of NUEDEXTA capsules containing 20 mg DM (Dextromethorphan)/10 mg Q (Quinidine) for treatment of Pseudobulbar Affect (PBA) in patients with…
- Conditions
- Pseudobulbar Affect (PBA), Stroke, Dementia, Traumatic Brain Injury (TBI)
- Trial name
- PRISM II (NCT01799941)
- Testing
- Nuedexta (DM 20 mg/Q 10 mg)
- Where
- United States
- Volunteers
- 367 people
- Sponsor
- Avanir Pharmaceuticals
Ischemic Stroke
Percutaneous Recanalization in Ischemic Stroke Management (PRIISM): A Feasibility Clinical Study
The primary study objective is to assess the feasibility of using the MindFrame System to safely and effectively restore blood flow in a thrombotic neurovascular occlusion in patients experiencing an ischemic stroke.
- Trial name
- PRIISM (NCT00810095)
- Testing
- MindFrame System
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- MindFrame, Inc.
Acute Ischemic Stroke
Cerebrolysin REGistry Study in Stroke - a High-quality Observational Study of Comparative Effectiveness
This study investigates the clinical practices, safety and effectiveness of Cerebrolysin in routine treatment of patients with moderate to severe neurological deficits after acute ischemic stroke.
- Trial name
- C-REGS2 (NCT03480698)
- Testing
- Cerebrolysin
- Where
- 8 sites in Austria
- Volunteers
- 1,851 people
- Sponsor
- Ever Neuro Pharma GmbH
Acute Ischemic Stroke
Study to Assess PK, Safety and Tolerability in Healthy Subjects
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of QHRD106 in Chinese healthy subjects with single and multiple doses.
- Trial name
- NCT06380699
- Testing
- QHRD106 Injection, Human Urinary Kallidinogenase
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Changzhou Qianhong Bio-pharma Co., Ltd.
Stroke
"Evaluation Of ALBA® Device for Upper Extremity Motor Function In Adults With Subacute And Chronic Acquired Brain Injury"
As part of the rehabilitation techniques, robotic equipment has been introduced for the rehabilitation of the upper extremity with promising results.
- Trial name
- NCT05824416
- Testing
- Experimental: ALBA, Conventional Therapy
- Where
- Chile
- Volunteers
- 32 people
- Sponsor
- uMov
Acute Ischemic Stroke
A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS
This is a multicenter, double-blind, single-dose, randomized, and placebo-controlled prospective Phase IIa clinical study, designed to evaluate LT3001 drug product versus placebo/control in subjects with AIS.
- Trial name
- NCT04091945
- Testing
- LT3001 Drug Product
- Where
- 10 sites in United States, Taiwan
- Volunteers
- 24 people
- Sponsor
- Lumosa Therapeutics Co., Ltd.
Upper Limb Spasticity Post-Stroke
Botulinum Toxin A Associated Costs in the Treatment of Upper Limb Spasticity Post Stroke
This study aims to estimate the costs of botulinum toxin A utilization in standard practice for the treatment of upper limb spasticity post-stroke in Portugal.
- Trial name
- P_Dysport_CS (NCT02384330)
- Where
- 3 sites in Portugal
- Volunteers
- 57 people
- Sponsor
- Ipsen
Stroke
Cytoflavin in the Complex Rehabilitation of Stroke Patients
It is known that the acute period of stroke occurs is accompanied by oxidative stress, when intense generation of reactive oxygen species (ROS) have a toxic effect, which causes oxidative degradation of proteins, lipids, nucleic…
- Trial name
- NCT05935787
- Testing
- Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid)
- Where
- 3 sites in Russia
- Volunteers
- 240 people
- Sponsor
- POLYSAN Scientific & Technological Pharmaceutical Company
Atrial Fibrillation (AF)
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called apixaban.
- Trial name
- ROXI-EVEREST (NCT07626411)
- Testing
- REGN7508, Apixaban
- Where
- 54 sites in United States, Canada and 1 more
- Volunteers
- 15,364 people
- Sponsor
- Regeneron Pharmaceuticals
Contraception, Female Contraception
Postmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Venous Thromboembolism (Blood Clots), Stroke and Heart Attacks
The purpose of the study is to assess the occurrence of venous thromboembolism (blood clots), stroke, and heart attack in current users of ORTHO EVRA compared to current users of norgestimate-containing oral contraceptives with…
- Trial name
- NCT00331071
- Testing
- Monophasic or triphasic Oral contraceptive tablet, Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE
- Volunteers
- 334 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Type 2 Diabetes Mellitus
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
The purpose of this study is to determine whether saxagliptin can reduce the risk of cardiovascular events when used alone or added to other diabetes medications
- Trial name
- SAVOR- TIMI 53 (NCT01107886)
- Testing
- Saxagliptin
- Where
- 536 sites in United States, Argentina and 25 more
- Volunteers
- 18,206 people
- Sponsor
- AstraZeneca
Ischemic Stroke
Navigated Transcranial Magnetic Stimulation in Monitoring Stroke Recovery
The past 10 years of research in persons more than 6 months post stroke have shown certain types of rehabilitation can help "re-wire" the brain.
- Trial name
- NCT01005394
- Testing
- Navigated TMS examination
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Nexstim Ltd
Stroke
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
The purpose of this study is to evaluate the safety and tolerability of SUN13837 and to determine whether SUN13837 improves the physical performance, relative to placebo, following an acute stroke in adult subjects.
- Trial name
- NCT02258880
- Testing
- SUN13837
- Where
- 53 sites in United States, Canada and 2 more
- Sponsor
- Daiichi Sankyo
Acute Ischemic Stroke
Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window (ImpACT-24A)
The primary objective of the study is to assess the safety and effectiveness of SPG stimulation with the ISS in patients with an acute ischemic stroke in the anterior circulation initiated within 24 hours from stroke onset.
- Trial name
- ImpACT-24A (NCT03767192)
- Testing
- Active Stimulation
- Where
- 8 sites in United States, Germany and 1 more
- Volunteers
- 327 people
- Sponsor
- BrainsGate
Acute Ischemic Stroke
A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)
The purpose of this study is to determine if YM872 in combination with t-PA can reduce disability and brain damage from stroke. YM872 or placebo will be given as a continuous intravenous (iv) infusion for 24 hours.
- Trial name
- NCT00044057
- Testing
- YM872 (zonampanel), t-PA (alteplase)
- Where
- 118 sites in United States, Austria and 3 more
- Sponsor
- Astellas Pharma Inc
Stroke
An Ischaemic Stroke Observational Study
A non-interventional observational clinical study to document the clinical course of patients at 12 months or more following an ischaemic stroke
- Trial name
- NCT03333980
- Where
- 7 sites in United Kingdom
- Volunteers
- 39 people
- Sponsor
- ReNeuron Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.